癌症合并静脉血栓栓塞患者的微粒体组织因子活性增加。
Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism.
机构信息
Division of Hematology/Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7035, USA.
出版信息
Thromb Res. 2010 Jun;125(6):511-2. doi: 10.1016/j.thromres.2009.09.019. Epub 2009 Oct 24.
Abstract
Cancer patients exhibit a high rate of thromboembolism (VTE). In this study, we analyzed levels of microparticle (MP) tissue factor (TF) activity in cancer patients with or without VTE. Blood was collected from cancer patients within 24 h of objectively diagnosed VTE (n=53) and from cancer patients without VTE (n=13). MPs were isolated from platelet poor plasma by centrifugation at 20,000g for 15 min. MP TF activity was measured using a two-stage chromogenic assay. Cancer patients with VTE had a significantly higher mean MP TF activity compared with cancer patients without VTE (1.7+/-3.8 pg/mL vs 0.6+/-0.4 pg/mL, p<0.05). Further prospective studies are required to determine if levels of MP TF activity may be a useful biomarker to identify patients at increased risk for VTE.
摘要
癌症患者血栓栓塞（VTE）发生率较高。在这项研究中，我们分析了伴有或不伴有 VTE 的癌症患者的微粒体（MP）组织因子（TF）活性水平。在客观诊断为 VTE 后 24 小时内采集癌症患者的血液（n=53），并采集无 VTE 的癌症患者的血液（n=13）。通过在 20,000g 下离心 15 分钟从血小板贫乏的血浆中分离 MPs。使用两步显色测定法测量 MP TF 活性。与无 VTE 的癌症患者相比，患有 VTE 的癌症患者的平均 MP TF 活性显著更高（1.7+/-3.8 pg/mL 比 0.6+/-0.4 pg/mL，p<0.05）。需要进一步的前瞻性研究来确定 MP TF 活性水平是否可以作为一种有用的生物标志物来识别 VTE 风险增加的患者。
相似文献
1
Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism.癌症合并静脉血栓栓塞患者的微粒体组织因子活性增加。
Thromb Res. 2010 Jun;125(6):511-2. doi: 10.1016/j.thromres.2009.09.019. Epub 2009 Oct 24.
2
High concentration of the plasma microparticles for venous thromboembolism associated with lung cancer.高浓度的循环微粒与肺癌相关的静脉血栓栓塞症。
Clin Respir J. 2020 May;14(5):481-487. doi: 10.1111/crj.13158. Epub 2020 Feb 19.
3
Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer.携带组织因子的微粒与炎症：癌症患者静脉血栓栓塞形成的潜在机制。
J Thromb Haemost. 2017 Dec;15(12):2289-2299. doi: 10.1111/jth.13871. Epub 2017 Nov 8.
4
Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients.微粒体相关组织因子活性、静脉血栓栓塞和胰腺癌、胃癌、结直肠癌及脑癌患者的死亡率。
J Thromb Haemost. 2012 Jul;10(7):1363-70. doi: 10.1111/j.1538-7836.2012.04754.x.
5
Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism.伴有和不伴有静脉血栓栓塞症的癌症患者中的内皮细胞、血小板和组织因子载带的微粒。
Thromb Res. 2011 May;127(5):473-7. doi: 10.1016/j.thromres.2011.01.002. Epub 2011 Jan 22.
6
Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity.影响血浆衍生微粒体组织因子活性测量的分析前和分析变量。
Thromb Res. 2012 Jan;129(1):80-5. doi: 10.1016/j.thromres.2011.06.004. Epub 2011 Jul 6.
7
Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study.癌症患者的凝血激活和微粒体相关凝血活性。一项探索性前瞻性研究。
Thromb Haemost. 2012 Jul;108(1):160-5. doi: 10.1160/TH12-02-0099. Epub 2012 Apr 26.
8
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.多发性骨髓瘤中微粒体相关组织因子活性与静脉血栓形成。
Thromb Haemost. 2011 Jan;105(1):14-20. doi: 10.1160/TH10-03-0187. Epub 2010 Nov 5.
9
Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role.胶质来源的循环微颗粒和组织因子在高级别神经胶质瘤中的表达：一种潜在的促血栓形成作用。
Thromb Haemost. 2013 Aug;110(2):378-85. doi: 10.1160/TH12-12-0957. Epub 2013 Jun 27.
10
Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.组织因子作为恶性肿瘤复发性静脉血栓栓塞的预测因子：CATCH 试验的生物标志物分析。
J Clin Oncol. 2017 Apr 1;35(10):1078-1085. doi: 10.1200/JCO.2016.67.4564. Epub 2016 Dec 28.
引用本文的文献
1
The Role of Platelet Dysfunctions in the Pathogenesis of the Hemostatic-Coagulant System Imbalances.血小板功能障碍在止血-凝血系统失衡发病机制中的作用。
Int J Mol Sci. 2025 Mar 19;26(6):2756. doi: 10.3390/ijms26062756.
2
Microvesicle Tissue Factor Procoagulant Activity Is Elevated and Correlated With Disease Severity in Patients With Cirrhosis.微泡组织因子促凝活性在肝硬化患者中升高且与疾病严重程度相关。
Liver Int. 2025 Apr;45(4):e16192. doi: 10.1111/liv.16192. Epub 2024 Nov 27.
3
Precision Oncology: Circulating Microvesicles as New Biomarkers in a Very Early Stage of Colorectal Cancer.精准肿瘤学：循环微泡作为结直肠癌极早期的新型生物标志物
Cancers (Basel). 2024 May 20;16(10):1943. doi: 10.3390/cancers16101943.
4
Selective but not pan-CDK inhibition abrogates 5-FU-driven tissue factor upregulation in colon cancer.选择性而非泛细胞周期蛋白依赖性激酶抑制可消除 5-FU 驱动的结肠癌组织因子上调。
Sci Rep. 2024 May 8;14(1):10582. doi: 10.1038/s41598-024-61076-5.
5
Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.脑肿瘤患者静脉血栓栓塞症的流行病学、生物学和管理：跨学科综述。
Neuro Oncol. 2023 Aug 3;25(8):1381-1394. doi: 10.1093/neuonc/noad059.
6
Effect modification of age and hypertension on cancer and prevalence of self-reported stroke - A cross-sectional study.年龄和高血压对癌症及自我报告卒中流行的作用修饰：一项横断面研究。
Cancer Med. 2023 Jun;12(11):12518-12523. doi: 10.1002/cam4.5964. Epub 2023 Apr 21.
7
Determining venous thromboembolism risk in patients with adult-type diffuse glioma.确定成人弥漫性脑胶质瘤患者的静脉血栓栓塞风险。
Blood. 2023 Mar 16;141(11):1322-1336. doi: 10.1182/blood.2022017858.
8
Hemostasis and cancer: Impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer.止血与癌症：止血生物标志物对癌症患者临床结局预测的影响。
J Thromb Haemost. 2022 Dec;20(12):2733-2745. doi: 10.1111/jth.15880. Epub 2022 Sep 27.
9
Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders.凝血的病理生理学以及细胞外囊泡在凝血级联反应和疾病中的新作用
J Clin Med. 2022 Aug 22;11(16):4932. doi: 10.3390/jcm11164932.
10
Proteomic Profile of Procoagulant Extracellular Vesicles Reflects Complement System Activation and Platelet Hyperreactivity of Patients with Severe COVID-19.严重 COVID-19 患者促凝细胞外囊泡的蛋白质组学特征反映了补体系统激活和血小板高反应性。
Front Cell Infect Microbiol. 2022 Jul 22;12:926352. doi: 10.3389/fcimb.2022.926352. eCollection 2022.
本文引用的文献
1
D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.D-二聚体和凝血酶原片段1+2可预测癌症患者发生静脉血栓栓塞：来自维也纳癌症与血栓形成研究的结果。
J Clin Oncol. 2009 Sep 1;27(25):4124-9. doi: 10.1200/JCO.2008.21.7752. Epub 2009 Jul 27.
2
Microparticle-associated tissue factor activity in cancer patients with and without thrombosis.伴有和不伴有血栓形成的癌症患者中微粒相关组织因子活性
J Thromb Haemost. 2009 Aug;7(8):1421-3. doi: 10.1111/j.1538-7836.2009.03504.x. Epub 2009 Jun 3.
3
Inflammation and liver cancer: new molecular links .炎症与肝癌：新的分子联系
Ann N Y Acad Sci. 2009 Feb;1155:206-21. doi: 10.1111/j.1749-6632.2009.03704.x.
4
Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer.血浆组织因子可能是胰腺癌静脉血栓栓塞的预测指标。
J Thromb Haemost. 2008 Nov;6(11):1983-5. doi: 10.1111/j.1538-7836.2008.03156.x. Epub 2008 Sep 15.
5
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).血浆中可溶性P选择素水平升高可预测癌症患者发生静脉血栓栓塞：维也纳癌症与血栓形成研究（CATS）的结果
Blood. 2008 Oct 1;112(7):2703-8. doi: 10.1182/blood-2008-02-142422. Epub 2008 Jun 6.
6
Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk?针对癌症患者进行抗凝预防试验的目标患者：谁的风险最高？
Thromb Res. 2007;120 Suppl 2:S29-40. doi: 10.1016/S0049-3848(07)70128-7.
7
Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis.血液凝固外源性途径在止血和血栓形成中的作用。
Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1687-93. doi: 10.1161/ATVBAHA.107.141911. Epub 2007 Jun 7.
8
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.血栓栓塞是接受门诊化疗的癌症患者死亡的主要原因。
J Thromb Haemost. 2007 Mar;5(3):632-4. doi: 10.1111/j.1538-7836.2007.02374.x.
9
Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer.组织因子表达作为卵巢癌血栓栓塞的一个可能决定因素。
Br J Cancer. 2007 Jan 29;96(2):290-5. doi: 10.1038/sj.bjc.6603552. Epub 2007 Jan 9.
10
Zotero 插件